Bob Hanlon, PhD is a co-founder and chairman of the Exon 20 Group, an advocacy organization focused on transforming cancers caused by EGFR and HER2 exon 20 insertion mutations into manageable diseases. He is also a Senior Lecturer in the Department of Chemical Engineering at the Massachusetts Institute of Technology (MIT), where he helps operate the School of Chemical Engineering Practice globally. Bob earned his PhD in Chemical Engineering at MIT and spent 23 years in industry (Mobil Oil R&D Corp, Rohm & Haas Co.) before returning to teaching. In 2016, his brother was diagnosed with Stage IV non-small cell lung cancer (EGFR exon 20 insertion) and, in his search for guidance, discovered Marcia Horn and the International Cancer Advocacy Network. Early discussions with Marcia led to the creation of the Exon 20 Group under ICAN's umbrella. The Exon 20 Group is a multi-stakeholder, global coalition comprised of patients, care partners, family members, thoracic and medical oncologists, scientists, molecular profiling labs, pharmaceutical companies, and biotechnology companies, with the mission of converting exon 20 insertion mutations into chronic diseases and ultimately curing them.